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Protein–protein interactions (PPIs) are central to biological mechanisms, and can serve as compelling
targets for drug discovery. Yet, the discovery of small molecule inhibitors of PPIs remains challenging
given the large and typically shallow topography of the interacting protein surfaces. Here, we describe
a general approach to the discovery of orthosteric PPI inhibitors that mimic specific secondary protein
structures. Initially, hot residues at protein–protein interfaces are identified in silico or from experimental
data, and incorporated into secondary structure-based queries. Virtual libraries of small molecules are
then shape-matched against the queries, and promising ligands docked to target proteins. The approach
is exemplified experimentally using two unrelated PPIs that are mediated by an a-helix (p53/hDM2) and
a b-strand (GKAP/SHANK1-PDZ). In each case, selective PPI inhibitors are discovered with low mM activity
as determined by a combination of fluorescence anisotropy and 1H–15N HSQC experiments. In addition,
hit expansion yields a series of PPI inhibitors with defined structure–activity relationships. It is envisaged
that the generality of the approach will enable discovery of inhibitors of a wide range of unrelated
secondary structure-mediated PPIs.Introduction
The discovery of small-molecule modulators of protein–protein
interactions (PPIs) is a central challenge in both chemical
biology andmedicinal chemistry.1–6 For a number of PPI targets,
potent PPI inhibitors and stabilizers have now been successfully
discovered, for example by optimisation of high-throughput
screening hits, fragment-based discovery approaches or virtual
methods targeting p53/hDM2,7–10 the BCL-2 family11–15 and
other interactions.16–21 However, the paucity of small-molecule
PPI inhibitors that have progressed as clinical candidates,3iology, University of Leeds, Woodhouse
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the Royal Society of Chemistrywithin the context of an enormous protein–protein inter-
actome,22 provides continued motivation for development of
novel and general small-molecule discovery approaches.
Although PPIs are known to involve shallow, relatively large
interfaces of varied topography, the identication of hot-
spots23,24 – i.e., amino-acid residues that contribute signicantly
to binding – can provide focus for ligand design efforts. More-
over, a signicant proportion of the protein–protein inter-
actome involves short linear peptide sequences that adopt
dened secondary structures, providing promising templates
for design of orthosteric peptidomimetic inhibitors.2,5
Design approaches can be categorized into four groups.5
Class A mimetics are peptides with a limited number of modi-
ed amino acids introduced to optimize properties (e.g. stapled
peptides). Class B mimetics are peptidic in nature but with
more dramatic changes to structure; they include foldamers
and mimic secondary structure topology. Class C mimetics are
topographical mimics and are more small-molecule like; a core
scaffold projects groups to mimic the orientation and compo-
sition of hot-spot residues. Class D mimetics are functional
mimics and do not necessarily have a connection to struc-
ture.25–29 Class C mimetics – also termed proteomimetics – have
successfully been developed to inhibit a range of a-helix-
mediated PPIs, in some cases with selectivity and cellular
activity.25–29 However, the proteomimetic approach has not beenChem. Sci.
Fig. 1 Schematic illustrating query-guided PPI inhibitor discovery in
which small-molecules can potentially mimic any secondary structure.
The discovery workflow is implemented through several stages that
combine established computational tools and experimental validation.
Initially a query is built that incorporates the key secondary structural
motif and hot residues from the PPI. A virtual library of small molecules
is then shape-matched against the query, and promising compounds
docked against the target protein. Candidate inhibitors are then sub-
jected to experimental screening and characterisation, enabling
selection of hits for: (i) clustering, near neighbour expansion and
further screening by reiteration of step II and III of the workflow; or (ii)
further development.























































































View Article Onlinewidely demonstrated for other classes of PPIs and generates
simplied ligands (more likely to have off-target effects) with
undesirable molecular properties (e.g. solubility, permeability)
and hence limited scope for optimisation.26 Extension of the
proteomimetic concept to small molecules with potential for
rational medicinal chemistry optimisation into drug-like PPI
inhibitors is therefore desirable.
Here, we exemplify a general approach for the discovery of
small-molecule proteomimetic inhibitors of PPIs (Fig. 1) which
we term: Query-Guided PPI Inhibitor Discovery. Hot-spot residues
from a protein–protein interface are built into secondary
structure-based queries. Assessment of the shape similarity30–36
of ligands to the query, in this case using FastROCS,30,31,33–36
enables small-molecule prioritisation. To provide additional
condence prior to experimental studies, further docking is
performed. We demonstrate the power of the approach using
two unrelated exemplar PPI targets: (i) p53/hDM2, an a-helix-
mediated PPI37 that is a clinically relevant oncology target;38
and (ii) GKAP/SHANK1-PDZ,39 a b-strand-mediated PPI whichChem. Sci.plays a key role at the synaptic junction40 and is representative
of PDZ-mediated interactions, which remain challenging for
small-molecule inhibitor discovery.41,42 For both targets, we
used this approach to virtually screen 4 million compounds
for which physical samples were available in AstraZeneca's
compound collection and then validated the approach experi-
mentally using uorescence anisotropy and 1H–15N HSQC
biophysical screens. Hit-expansion for the p53/hDM2 inhibitor
identied a series of PPI inhibitors with dened structure–
activity relationships demonstrating the approach identies
developable compounds.
Results and discussion
Discovery of small-molecule p53/hDM2 inhibitors
We used the p53/hDM2 interaction as an exemplar PPI to
benchmark our discovery approach. The p53/hDM2 interaction
involves thirteen residues of the disordered N-terminal trans-
activation domain of p53 (p5317–29 henceforth referred to as
p53), which folds into a helix and docks into a hydrophobic cle
on hDM2 (Fig. 2a).37 Three key side chains – Phe19, Trp23 and
Leu26 – located on one face of the helix (at the i, i + 4 and i + 7
positions), have been identied as making a dominant contri-
bution to the binding free energy of association (Fig. 2a and
b).43,44 These hot residues were used to construct queries for
structure similarity searching. First, the p53 peptide was excised
from a structure of p53/hDM2 (PDB: 1YCR), and a query was
generated that contained the three hot-spot residues linked by
a hydrocarbon backbone (Fig. 2c). A second query was gener-
ated in which a peptide backbone was retained (Fig. 2d).
A virtual library of 42 million conformers based on the
AstraZeneca screening collection was shape-matched against
both queries using FastROCS.30,31,33–36 For each query, the top
1000 hit conformers, based on the sum of the scoring functions
for 3D shape match and surface complementarity, were
selected. These conformers were then docked rigidly to hDM2
(OEDocking; ©2019, OpenEye Scientic Soware, Inc.),45–49 and
scored with a hybrid function that captured both shape simi-
larity to the bound p53 peptide and shape complementarity to
the hDM2 binding site (Fig. 1, stage II, see Fig. S1† for more
detailed workow including clustering,50 near neighbour
expansion and further screening which can be reiterated as
appropriate, and, ESI† for methodology). Next, the virtual hits
were triaged ahead of experimental evaluation (Fig. 1, stage III).
First, we removed fragment-like hits, a decision informed by
observations made in the deconstruction of the known inhib-
itor RG7112: this retrospective analysis suggested a fragment-
based discovery approach would only have been possible by
starting with fragments that retained at least two hot-spot
binding groups.51 Second, a signicant number of compounds
were removed because they had ipped during docking (i.e., the
docked pose no longer adopted a p53 mimicking orientation),
and therefore did not t with the design hypothesis. Third, the
remaining hits were clustered (Tanimoto similarity >0.7), and
one or two representatives were retained from each cluster (see
ESI†); clusters with singleton hits were only retained if there was
at least one near-neighbour in the main AstraZeneca screening© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 2 Discovery of small-molecule inhibitors of the p53/hDM2 interaction: (a) close-up of the p53/hDM2 interaction structure (PDB ID: 1YCR),41
p53 (cyan), with key side chains Phe19, Trp23 and Leu26 highlighted, docks into the hDM2 cleft with the hDM2 surface defined by the Phe19
(violet), Trp23 (magenta) and Leu 26 (green) pockets, into which each corresponding hydrophobic amino acid projects; (b) ribbon representation
of the p5317–29 transactivation domain with key side chains Phe19, Trp23 and Leu 26 highlighted together with the primary sequence (below); (c)
query that incorporates the hot residues and a “hydrocarbon” backbone; (d) query that incorporates the hot residues and a peptidic backbone. (e)
Overlay of exemplar shape-matched hit compounds and queries; (f) structures of the exemplar hit compounds as representatives of the most
populated clusters; (g) ligand efficiency plot for the 37 hits obtained from the computational workflow (LE ¼ 1.4  pIC50/nHA, nHA: number of
non-hydrogen atoms, IC50 obtained by fluorescence anisotropy competition: 150 nM hDM2 and p5315–31Flu, 40mMphosphate, pH 7.4, 200mM
NaCl and 0.02 mg ml1 BSA); (h) mapping of the chemical shift perturbations in hDM2 for hit compounds from cluster A, cluster B and cluster C.
Colour variation is associated with a chemical shift perturbation that goes from 0 ppm (white) to 0.2 ppm (red).























































































View Article Onlinecollection. For each query, 100 compounds were prioritised
for experimental evaluation, including representatives of the
top 30 clusters that were predicted to interact with at least two
hot residue binding pockets. In addition, 100 randomly selected
compounds were also selected for analyses (see ESI†).
The ability of compounds to displace a uorescently labelled
p53 peptide (p5315–31Flu (L31C), Flu¼ uorescein-5-maleimide)© 2021 The Author(s). Published by the Royal Society of Chemistrywas determined using a competition uorescence anisotropy
assay (see ESI Fig. S2† for assay and Fig. S3–S6† for % inhi-
bition at 10 and 100 mM). For compounds that displayed
signicant activity at 100 mM, structurally similar near-
neighbours were selected from the main AstraZeneca
screening collection for hit expansion. For the query with
a hydrocarbon backbone, 21 hits from 15 clusters wereChem. Sci.
Fig. 3 Development of a GKAP query for inhibitor screening against the GKAP/SHANK1-PDZ interaction; (a) close-up of the GKAP/SHANK1 PDZ
interaction structure (PDB ID: 1Q3P),43 GKAP (cyan), with key side chains Thr3 and Leu5 highlighted, interacts with SHANK1 PDZ domain mainly through
polar contacts (orange area); however, hydrophobic effects play a significant role in binding (magenta area); (b) cartoon representation of the GKAP1–5
peptide with key side chains Thr3 and Leu5 highlighted together with the primary sequence (below); (c) X-ray crystal structure of Ac-Glu-Ala-Gln-Thr-
Arg-Phe peptide (L6F) bound to SHANK1-PDZ (PDB ID: 7A00) illustrating good correspondence with the position of key recognition groups observed for
the wild-type sequence (PDB ID: 1Q3P); (d) close up of the interactions between the C-terminus of the L6F GKAP peptide and SHANK1 PDZ (H-bonds
orange, other contacts yellow dashed lines); (e) close up of the interactions between theC-terminus of thewtGKAP peptide and SHANK1 PDZ; (f) binding
of wild type (left) and L6F (right) GKAP peptide to SHANK1, monitored by ITC (25 C in 20 mM Tris, 150 mM NaCl, pH 7.5, heats of peptide dilution were
subtracted from eachmeasurement raw data) with data analysed usingMicrocal Origin 8 and fitted to a one-binding sitemodel; (g) GKAP query whereby
theThr3 side chain is retained togetherwith a Phe in lieuof a Leu side chain alongside key backbonedonor (NH) and acceptor (CO) groups; (h) structure of
the hit compoundsZ-1 andZ-2 identified from single point screeningworkflowusing the query in panel (g); (i) overlay of the compoundZ-1 and thequery
(grey); (j) fluorescence anisotropy competition assay for compound Z-1 (FITC-GKAP 50 nM, SHANK1-PDZ 1 mM, pH 7.4, 20mMTris, 150mMNaCl, 0.01%
Triton-X-100 buffer); (k) expansion of the 1H–15N HSQC spectra of 15N labelled SHANK1 in the absence (red) and presence of compound Z-1 (com-
pound : protein molar ratio 1 : 1 yellow, 2 : 1 green, 4 : 1 blue). Peaks indicated with asterisk undergo significant changes in intensity upon binding
(SHANK1-PDZ 50 mM, pH 7.4, 5 mM Tris, 100 mM NaCl buffer).
Chem. Sci. © 2021 The Author(s). Published by the Royal Society of Chemistry















































































































































































View Article Onlineidentied, and were complemented with 100 near-
neighbours. For the query with the peptide backbone, 3
hits from 3 clusters were identied, and were complemented
with 11 near-neighbours. These 135 compounds were eval-
uated at 10 mM and 100 mM in the competition uorescence
anisotropy assay (not shown). Subsequently, based on visual
inspection and team discussion of how well they matched
the initial FastROCS shape-match and docking, alongside
medicinal chemistry and synthetic assessment, 63
compounds from 9 clusters (e.g. Fig. 2e and f) were selected
for IC50 determination (Fig. S6†). A number of these
compounds had mediocre inhibitory potency that fell
outside the assay window leaving 37 compounds for which
IC50 values could be determined, allowing an assessment of
their ligand efficiency (Fig. 2g), i.e. the binding energy per
non-hydrogen atom of a ligand to its binding partner which
is commonly used in drug discovery programmes to assist in
identifying compounds with optimal combinations of
properties.52,53
Mapping of chemical shi perturbations by 1H–15N HSQC
for representatives from each promising cluster conrmed
a bona de interaction with hDM2 (Fig. 2h and S7–S9†). We
used ligand efficiency scores and chemical accessibility to
eventually select compound A1 (Fig. 2) as a hit upon which to
carry out structure activity relationship (SAR) analysis (see
later and Fig. 4). At IC50 ¼ 7.9 (0.9) mM, hit compound A1
with MW ¼ 444 is only one order of magnitude lower in
inhibitory potency than Nutlin-3 (IC50 ¼ 0.6  0.04 mM; MW
¼ 581, see ESI Fig. S8†). However, it has a comparable ligand
efficiency of 0.24 (versus 0.22 for Nutlin-3) and signicant
potential for further derivatization and optimization.
Compound A1 was also shown to induce shis in the 1H–15N
HSQC spectrum and when mapped onto the residue
assignments, the affected resonances corresponded well to
those affected upon binding of Nutlin-3, lending support to
the design hypothesis. Compound A1 was also tested in a FA
competition assay for BID/MCL-1 (Fig. S10†), a further a-
helix mediated PPI: no inhibition was observed, indicating
the compound A1 to be selective and conrming it as a good
choice for further development.Application of the discovery workow to GKAP/SHANK1-PDZ
Subsequently, we applied the same workow to the GKAP/
SHANK1-PDZ interaction (Fig. 3). The GKAP PDZ-binding
motif (Ac-Glu-Ala-Gln-Thr-Arg-Leu-CO2H), henceforth referred
to as GKAP contains the known Type-I PDZ recognition motif:54
Thr-Xxx-Leu, with the C-terminal carboxylate making three
essential hydrogen bonds with backbone amide hydrogen
atoms in a loop on SHANK1 (Fig. 3a, orange area, PDB ID:
1Q3P).39 In our prior studies, computational modelling using
BudeAlaScan55,56 and experimental analyses conrmed the Thr
and Leu amino acids together with the terminal carboxylic acid
as crucial for binding (Fig. 3b).55,56 Although SHANK1 has
a dened hydrophobic cavity in which the Leu side chain of
GKAP is accommodated (Fig. 3a, magenta area), it represents
a signicantly more challenging target for small-molecule© 2021 The Author(s). Published by the Royal Society of Chemistrymimicry than p53/hDM2. As a b-strand mediated PPI, the
GKAP/SHANK1 interface relies on both side-chain contacts and
an extensive hydrogen bond network that plays an active role in
molecular recognition (Fig. 3a, d and e, H-bonds are shown as
orange dashed lines); these features are not readily reproduced
by typical (oen hydrophobic) small molecule scaffolds. Thus,
for query generation, the key hot residues of GKAP together with
backbone heteroatoms were used. However, when our workow
was implemented with a query bearing these features, we
identied only exible peptide-based inhibitor candidates (not
shown).
We reasoned that the C-terminal leucine, with more side-
chain degrees of freedom, might have contributed to the
moderate results in our in silico structure similarity anal-
yses. The plasticity of PDZ domains allows the accommo-
dation of various hydrophobic side chains at the C-terminus
of the peptide; for SHANK1, Leu dominates for C-terminal
carboxylates, however Phe has been observed to dominate
for non-C-terminal sequences.57,58 Therefore, we considered
Phe, with its more rigid hydrophobic amino acid sidechain,
as a suitable surrogate in this position of the query. Grati-
fyingly, preparation of the Ac-Glu-Ala-Gln-Thr-Arg-Phe-CO2H
peptide and assessment by isothermal titration calorimetry
conrmed the Phe variant peptide to be tolerated (Kd ¼ 5
(0.5) mM compared with Kd ¼ 2 (0.3) mM for the GKAP
sequence) and to act as an effective inhibitor (Fig. 3f and
S11† for uorescence competition anisotropy assay data
using FAM-Ahx-Glu-Ala-Gln-Thr-Arg-Leu-CO2H as tracer).
We obtained a peptide/protein co-crystal structure conrm-
ing the Phe to be a viable substitution for the C-terminal Leu
(PDB ID: 7A00). The structure (Table S1† for Data collection
and renement statistics) reveals that the L6F variant
peptide binds in the PDZ-binding site and reproduces many
of the key recognition features and similar orientation of
side chains, albeit with subtle differences (Fig. 3c–e).
Application of the in silico screening workow to a modi-
ed query with the Phe substitution (Fig. 3g) identied
a number of small-molecule candidate inhibitors (e.g.
Fig. 3h, i and S12†). These candidates were screened in
a uorescence anisotropy competition assay at 30 and 300
mM following a similar approach to that pursued for the p53/
hDM2 interaction, although a smaller number of less potent
hits were obtained. Compound Z-1 had an IC50  300 mM in
a uorescence anisotropy competition assay (Fig. 3j). The
moderate potency is deceiving; the low molecular weight
(294 Da) and promising ligand efficiency (LE: 0.24) render it
a promising starting point for subsequent optimization.
1H–15N HSQC perturbation shis indicated interaction of
the ligand with the SHANK1-PDZ domain (Fig. 3k and S13†),
however in these analyses the absence of assignments pre-
vented mapping of a putative binding site. Compound Z-1
has signicant similarity to a recently-reported small-
molecule ligand for SHANK3: compound Z-2.59 We synthe-
sized and tested compound Z-2 in the uorescence anisot-
ropy competition and 1H–15N HSQC assays (see ESI†); these
experiments conrmed that compound Z-2 also acts asChem. Sci.
Fig. 4 Development of p53/hDM2 inhibitors, (a) synthetic route to hit A1; (b) selected chemical structures and associated IC50 values (fluo-
rescence anisotropy competition: 150 nM hDM2 and p5315–31Flu, 40 mM phosphate, pH 7.4, 200 mMNaCl and 0.02 mgml
1 BSA) of developed
inhibitors (increasing colour intensity of the wedges denotes increased potency, *reduced anisotropy in the assay attributed to solubility †non-
specific interactions observed); (c) ligand efficiency plot for selected inhibitors shows exploration of the chemical space starting from selected hit
A1 (green sphere). Coloured shapes are assigned to describe inhibitors from the first (triangle), second (square, diamond and inverse triangle) and
third series (star). (d) Mapping of chemical shift perturbations in hDM2 for selected inhibitors (750MHz, 100mM phosphate, pH 7.4, 2.5% glycerol,
1 mM DTT, increasing concentration of compound was titrated into 50 mM hDM2 and CSP wasdetermined at 1 : 2 protein : compound ratio).
Colour variation is associated with a chemical shift perturbation from 0 ppm (white) to 0.2 ppm (red).
Chem. Sci. © 2021 The Author(s). Published by the Royal Society of Chemistry















































































































































































View Article Onlinea GKAP/SHANK1-PDZ inhibitor (IC50  110 mM in competi-
tion assay, see ESI Fig. S14†).
Query-guided hit identication provides useful starting points
for PPI inhibitor elaboration
To illustrate the application of our approach to the identica-
tion of useful starting ligands for further optimization, we
carried out structure–activity relationship analysis on one of the
p53/hDM2 inhibitor series. Aer a synthetic route was estab-
lished (Fig. 4a and Schemes S1–S3†), the original hit A1 was
resynthesized together with a series of derivatives (Fig. 4b for
selected compounds). For the rst series, full competition
anisotropy experiments and NMR titrations (Fig. S15 and Table
S2† for competition data and Fig. S16† for representative HSQCFig. 5 Molecular dynamics simulation of hit compound A1 indicates
coexistence of two conformations at the hDM2 binding site. (a) Root
mean square deviations during a 10 nanoseconds molecular dynamics
simulation of A1/hDM2. Red represents the core and green represents
the tail. (b) Chemical structure of A1 highlighting core and tail. (c) MD
snapshot at 0 ns shows the folded conformation, which occupies only
two of the three hot-spots, (d) MD snapshot at 8 ns shows the
extended conformation which occupies the three hot-spots. p53 hot
residue side chains are shown in cyan, Phe19, Trp23 and Leu26
pockets of hDM2 are highlighted in violet, magenta and green,
respectively.
© 2021 The Author(s). Published by the Royal Society of Chemistryspectra) were performed for these (racemic) compounds,
revealing compounds A1, 8a and 8b to be the most potent in the
series (Fig. 4b). The loss of activity upon exchange of the 5-
chloro-2-thiophene ring for a benzene ring (compounds 9a–9d)
and the hydrophobic amide linker length (compound 7c) point
to a key role of these groups as determinants of inhibition.
Indole ring modications and pyridine-to-benzene substitution
were tolerated; however, an aromatic group in this position was
necessary (analogues 7b and 8b versus analogues 7d and 8c).
Although we screened multiple crystallisation conditions,
crystals of the A1/hDM2 complex were not obtained. Therefore,
to rationalise the initial SAR and further investigate the binding
mode of A1, we carried out molecular dynamics (MD) simula-
tions (Fig. 5). The root mean square deviations (RMSD) of the
atomic positions of the ligand over a 10 nanosecond simulation
of the R-A1/hDM2 complex revealed important features. The
indole and thiophene rings of R-A1 formed a xed core occu-
pying the Trp23 and Phe19 pockets, respectively. In contrast,
the (pyridin-2-yl)ethyl moiety appeared to ip between two
different positions, as a consequence of rotation about the CO–
Ca carbon bond and the inherent exibility of the ethyl linker
(Fig. 5c and d). Interestingly, only one of those positions occu-
pied the shallower Leu26 pocket, which corresponds to an
extended conformation of the inhibitor. This behaviour was
replicated in a longer 200 ns MD simulation (Fig. S17a and
Movie R-A1†). For the S-enantiomer the initial docked poses t
less well to the design hypothesis; for one pose the thiophene
was placed in the W23 site whilst the other pose placed the
indole in the W23 site, however, in both simulations the
remaining arms were more dynamic indicating a poor correla-
tion with the design hypothesis (Fig. S17b, c, Movies S-A1-I and
II†). Given the extended conformation of R-A1 was shown to
best overlay with the three p53 hot-spot residues, we assumed it
to be the most active conformation. Therefore, we developed
a second series of inhibitors focusing on stabilisation of the
extended conformation.
For the second series, we introduced modications at three
different positions of the hit structure A1: methyl substituents
on the a carbon of the CO–Ca bond, cyclic constraints at the
ethyl linker moiety and halogen, and, carboxylic acid or amide
substituents at the C2-indole position (Fig. 4b, S15, S16 and
Table S2†). These modications were anticipated to increase
steric congestion adjacent to the CO–Ca bond, restricting the
accessible conformations in favour of the extended conforma-
tion with concomitant improvement in inhibitory potency
(hypotheses supported by MD simulations Fig. S18–S21,† see
below). Compounds anti-10, 11a and 11b were identied as the
most potent inhibitors from this second series (see Fig. S22 and
S23† for syn/anti assignment). Although there is still a two- to
ve-fold difference in potency in comparison to Nutlin-3, the
improved ligand efficiency (0.28 11a and 0.26 for anti-10 and
11b versus 0.22 for Nutlin-3) corroborates their potential as hits
for development of drug-like p53/hDM2 inhibitors. The poten-
tial for further development of this series is underscored by the
fact that it is possible to increase potency without marked
increase in heavy atom count. Restriction of the CO–Ca bond
with a gem-dimethyl group in 12 had no effect upon inhibition,Chem. Sci.























































































View Article Online(IC50  8 mM), whereas single methyl analogues resulted in
a signicant variation in inhibitory activity. Diastereomer anti-
10 inhibits the p53/hDM2 interaction with an IC50 ve times
smaller than syn-10. Resolution of the anti-10 enantiomers by
chiral HPLC (>99.0% ee, see Fig S24 and 25†) allowed us to test
them separately, with both showing comparable potency (3.1
mM for anti-10, 4.6 mM for ()-anti-10 and 2.9 mM for (+)-anti-10).
MD simulations were performed to explore behaviour of the 4
stereoisomers of 10 to determine which best ts the p53
binding site of hDM2. Although more complex behaviour was
observed, the simulations validate the hypothesis that restric-
tion of the conformational mobility improves inhibitor potency
(Fig. S18 and S19, Movies RR-10, SS-10, RS-10 and SR-10†).
Compound 7a with a constrained ethyl linker appeared to have
good inhibitory potency, however, although HSQC analyses
were consistent with effective binding, a lower anisotropy was
observed in the assay which we attribute to poor solubility.
Nonetheless, one of the 8 stereoisomers was subjected to MD
simulation; this was generated by adding the cyclopropyl ring to
R-A1 in the only position compatible with the bound confor-
mation and the constraints of the binding site. Bound 7a shows
particularly low mobility (Fig. S20 and Movie 7a†) consistent
with the design hypothesis.
Modications at the C2-indole position also induced a notable
increase in potency; derivatisation with a bromine in 11a and
a carboxylic acid in 11b. For derivatives 11a and 11d, the signicant
difference in activity (1 mM versus 13 mM) was attributed to
a regioisomer effect arising from the presence of both the bromine
and chlorine substituents. In the absence of the bromine, the
regioisomers A1 and 8a (8 mM versus 6 mM) elicited similar poten-
cies, pointing to a potential synergy between the orientation of the
indole in the Trp23 pocket and the orientation of the other two hot-
spot mimicking groups. Inhibitor 11b was also observed to have
increased potency; MD simulations place the 5-chloroindole ring
deep in the Trp23 pocket, projecting the C2-indole carboxylate
toward the edge of the a2 helix of hDM2 (see Fig. S21 Movies R-11b
and S-11b†).27 This would permit additional hydrogen bonds,
although a water mediated interaction has been observed for C2-
carboxylate indole substituted p53/hDM2 inhibitors.60–62 More
signicantly, the simulation on both R-11b and S-11b supports the
notion that the C2-indole substitution impedes back folding of the
pyridyl group to enforce an extended conformation (Fig. S21,
Movies R-11b and S-11b†). Amides 11e and 11f, bearing terminal
polar ionic groups, had moderate potency (13 mM and 25 mM,
respectively), whereas amides 11g–11i, with apolar substituents,
were poorer inhibitors. These observations are consistent with the
hypothesis51 that C-2 indole substituents promote a bioactive
conformation, while directing one substituent into the Phe19
pocket the C2-indole substituent acts as a cap shielding the
hydrophobic molecule from solvent. Finally, the combination of
methyl substituents on the a carbon of the CO–Ca bond or C2-
indole substitution and a constraint on the ethyl linker also resul-
ted in potent compounds (13, IC50 ¼ 1.2 (0.4) mM and 14, IC50 ¼
2.2 (0.5) mM, Fig. 4b). We then performed 1H–15N HSQC experi-
ments on thesemost potent inhibitors anti-10, 11a, 11b and 13 and
mapped their chemical shi variations onto the hDM2 protein
(Fig. 4d and Fig. S16†). In all cases, the major chemical shiChem. Sci.variations included amino acids Leu54, Gly58 and Val93, while less
pronounced shiswere observed for less potent compounds (e.g. 12
see Fig. 4d). These amino acids are located around the three hot-
spot pockets, thus the perturbations arising from binding of the
small-molecules can be attributed to recognition of the hydro-
phobic p53 binding cle of hDM2.Conclusions
In summary, we have used query-guided inhibitor discovery to
identify small-molecule inhibitors of the p53/hDM2 and GKAP/
SHANK1 interactions. For each interaction, a computational
workow that involved FastROCS matching to secondary structure
queries identied candidate inhibitors. Experimental screening of
subsets of these candidates identied multiple genuine inhibitors
demonstrating the approach to be valid for improving hit rate.
Characterization of the most-promising compounds using two
orthogonal assays identied inhibitors for both targets with
promising ligand efficiency, which bound at the anticipated
binding site and could be further developed. For instance starting
with 200 compounds for experimental screening against p53/hDM2
we obtained IC50 values for 37 compounds. This demonstrates the
strong performance of the computational workow considering
that high-throughput or fragment screening typically require >1
million or 103 compounds respectively to be screened to obtain
similar numbers of hits to take forward. Although the approach is
less likely to identify inhibitors that rely on induced conformational
changes – indeed Nutlin-like compounds (which are known to have
subtly different interactions with the dynamic hDM2 surface when
compared to p53)7 are in the AstraZeneca compound collection, but
were not scored in the top 1000 hits identied for experimental
screening – this represents an excellent hit rate. Whilst proteomi-
metics have been used to inhibit a range of intracellular a-helix-
mediated PPIs, there remains a need to broaden the method-
ology to other targets and use the conceptual framework to identify
small molecules that can be developed further.63–66 This study also
emphasizes that identication of non-a-helix mediated PPI inhib-
itors e.g. b-strand-mediated PPIs is more difficult, although the
identication of inhibitors for a strand-mediated interaction with
a PDZ domain, albeit with a signicantly lower hit-rate represents
the rst steps towards such a goal. Similarly, pharmacophore-based
virtual screening approaches whereby key hot-spot residues have
been used as an anchor67 have also recently been introduced, but to
date brought to bear only on targets with a dominant hot residue.
Taken together, our new approach harnesses the best of both
worlds to identify and prioritise small-molecules thatmimic diverse
secondary structures and inhibit PPIs broadening the proteomi-
metic concept beyond a-helix mediated PPIs and extending it to
genuine small-molecule ligands.Author contributions
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